I'm LongbridgeAI, I can summarize articles.Shanghai STAR Market Daily, May 5 – Recently, Changzhou Boyi Technology Group Co., Ltd. (hereinafter referred to as "Boyi Group") completed a Series B2 financing round of nearly RMB 100 million. This round was led by Zero2IPO Industrial Investment, with follow-on investments from the Jiangsu Changzhou High-End Functional Materials Industry Special Fund of Funds (Limited Partnership), the Jiangsu Huai'an Digital Intelligence Manufacturing Industry Special Fund of Funds (Limited Partnership) under the Huaichuang Venture Capital Group, and existing shareholders Jinyu Maowu and BGI Songhe, along with strategic investors.
The funds from the Series B financing will be primarily used for the research and development of new materials and intelligent protein purification systems, accelerating global commercial promotion and implementation.
Boyi Group has completed nearly RMB 100 million in Series B1 and B2 financing rounds. Existing shareholders Jinyu Maowu and BGI Songhe continued to participate in this round.
According to data from Cailianshe Venture Connect – Zhizhong, using November 2026 as the forecast baseline, the probability of Changzhou Boyi Technology Group Co., Ltd. securing further financing in the subsequent two years is 56.8%.
Founded in January 2022 and headquartered in Wujin District, Changzhou City, Jiangsu Province, Boyi Group is committed to becoming an influential provider of intelligent protein research solutions.
The core team, led by General Manager Fang Li, has focused on microspheres as its core product for over a decade. It is a professional, dedicated, and entrepreneurial young team.
In its early stages, the company developed various fillers such as agarose and dextran, achieving 100% proprietary technology and self-production of core raw materials. Currently, it has built 10 fully automated production lines with a single-batch capacity of 10,000 liters. Recently, it launched "Qianzhang," a full-process AI agent for protein purification scenarios, which can assist in generating pilot-scale plans.
The company has formed a matrix of over 300 purification products. The 10 fully automated production lines at its new headquarters have been put into use, doubling the capacity for precast gels. It has signed a strategic cooperation agreement with BGI Yongsheng Intelligence to integrate resources in protein purification and automated intelligent equipment, exploring paths for the intelligent upgrade of biomanufacturing.
The research and production of intelligent protein purification systems are accelerating the integration of AI technology, while leading companies continue to expand capacity and intensify competition.
Regarding the competitive landscape, Nanomicro Tech's sales revenue growth for microsphere products used in drug synthesis and separation/purification reached over 40% year-on-year. Sepax Technologies' designed annual production capacity is 3,000 kilograms of protein and 18 tons of silica-based fillers.
Regarding industry trends, Bank of China Securities pointed out that demand for AI-driven drug discovery (AIDD) is transmitting to wet lab experiments and validation stages, suggesting that upstream scientific research-related enterprises are likely to benefit first. Biocytogen, Novoprotein, and Vazyme are focusing on enhancing their capabilities in the expression, purification, and in vitro validation of AI-designed molecules. Sepax Technologies and Nanomicro Tech are applying AI-assisted design to the development of affinity chromatography media.
Regarding industry risks, Bank of China Securities noted that the recovery of innovative drug investment, financing, and R&D spending may fall short of expectations; growth in new CXO orders, improvement in order pricing, and conversion of existing orders may not meet expectations; and the iteration and industrialization progress of AIDD technology may lag behind expectations.